and Koreans have used its leaves as an antidiarrheal. 3 The presence of metabolites including gallic acid and flavonoids from previous investigations on C. walteri was confirmed.
2,3
Extracts of C. walteri were found to inhibit NO production in lipopolysaccharide (LPS)-activated macrophages. 4 Extracts also inhibited elastase and tyrosinase, and had anti-hyperglycemic, and anti-obesity effects. 5, 6 In our search for bioactive constituents from Korean medicinal plants, we found that a methanol extract of stems and stem bark of C. walteri had considerable cytotoxicity against some cancer cell lines, 7 and recently reported the identification of triterpenoids with cytotoxicity from the n-hexane-soluble fraction of the extract. 7 In our continuing efforts to study the active constituents of the MeOH extract, six δ-valerolactones (1) (2) (3) (4) (5) (6) were isolated from the CHCl 3 -soluble fraction of the MeOH extract using bioassay-guided fractionation ( Figure 1 ). Two of these compounds (1-2) are new, while two others (3) (4) have been previously reported but only as synthetic products. We report herein the isolation, structural elucidation (1) (2) (3) (4) , and cytotoxicity of all of the isolated compounds. 
Notes
were also observed and the (Table 1) . However, the optical rotation of 2 ( : +28.3) was almost of the same value but of opposite sign to that of 1 ( : −31.5), which suggested that compound 2 could be an enantiomer of 1. Similarly as described for 1, the absolute configuration of C-5 in 2 was determined using a modified Mosher's method, 7 which proved the S-configuration for C-5 ( Figure 3 , see the Supporting Information). Thus, compound 2 was characterized as (S)-5,6-dihydro-5-hydroxy-4-methyl-2H-pyran-2-one (walterolactone B). (Table 1) were almost identical to each other, and displayed the presence of one ester carbonyl, one methyl, two methylenes, one methine, and one hydroxylated methine, which were in agreement with those of cis-β-methyl-γ-hydroxy-δ-valerolactone. 8 The planar structures of 3 and 4 were confirmed by 2D NMR experiments (Figure 2 ). The COSY spectrum revealed a spin system composed of H-3/H-4/H-5/H-6, and HMBC correlations of H-7/C-3, H-7/C-5, H-5/C-3, H-4/C-2, and H-6/C-2 were shown in their HMBC spectrum ( Figure  2) , indicative of the presence of a methyl group at C-4 and an ester carbonyl group at C-2. The cis-configuration between the methyl group at C-4 and the hydroxyl group at C-5 of 3 and 4 was assigned by the chemical shift (δ H 4.13 for 3; δ H 4.13 for 4) of H-5, which was in agreement with that of cis-β-methyl-γ-hydroxy-δ-valerolactone (δ H 4.12-4.18 for cis-form; δ H 4.50-4.55 for trans-form).
8 Finally, their absolute configuration of C-5 was determined using the modified Mosher's method as described for 1, 7 which proved the S-configuration for C-5 of 3 and the R-configuration for C-5 of 4 ( Figure 3 , see the Supporting Information). Therefore, the structures of 3 and 4 were elucidated as (4S,5S)-tetrahydro-5-hydroxy-4-methyl-2H-pyran-2-one (walterolactone C) and (4R,5R)-tetrahydro-5-hydroxy-4-methyl-2H-pyran-2-one (walterolactone D), respectively.
Known compounds were identified as (R)-4-methyltetrahydro-2H-pyran-2-one (5) 9 and 4-methyl-5,6-dihydro-2-pyranone (6) 10 by comparison of physicochemical and spectroscopic data with previously reported literature values. To the best of our knowledge, this is the first study to report the presence of δ-valerolactones in the genus Cornus. In this study, the cytotoxicities of 1-6 against the A549, SK-OV-3, SK-MEL-2, and HCT15 human cancer cell lines were evaluated using the Sulforhodamine B (SRB) bioassay in vitro. 11 The results of this bioassay (Table 2) showed that all the tested δ-valerolactones (1-6) exhibited consistent cytotoxicity against the SK-MEL-2 cell line with IC 50 values in the range of 4.75-28.43 μM. In particular, compound 6 showed significant cytotoxicity against all of the cell lines tested with IC 50 values of 28.45, 5.76, 4.75, and 28.12 μM, respectively, for the A549, SK-OV-3, SK-MEL-2, and HCT-15 cell lines. These bioactivity data suggest that these compounds may be good bioactive molecules for the treatment of various cancers.
Experimental Section
Plant Materials. Stems and stem bark of C. walteri were collected on Jeju Island, Korea, in October, 2005, and the plant was identified by one of the authors (K.R.L.). A voucher specimen (SKKU 2005-10a) was deposited in the herbarium of the School of Pharmacy, Sungkyunkwan University, Suwon, Korea.
Extraction and Isolation. Stems and stem bark of C. walteri (2.5 kg) were dried, chopped, and extracted with 80% MeOH (2 × 6 h) under reflux and filtered. The filtrate was evaporated under vacuum to obtain a MeOH extract (220 g), which was suspended in distilled H 2 O (7.2 L) and then successively partitioned with n-hexane, CHCl 3 , and nBuOH, yielding 9.5, 25.0, and 43.0 g of residue, respectively. Each fraction was evaluated for cytotoxicity against human tumor cell lines, the A549, SK-OV-3, and SK-MEL-2 cell lines, using a SRB bioassay. We selected the CHCl 3 -soluble fraction for current phytochemical investigation, since the CHCl 3 -soluble fraction showed significant cytotoxic activity against tested tumor cell lines. Purification of six δ-valerolactones (1-6) was described in the Supporting Information.
Walterolactone A (1) Preparation of the (R)-and (S)-MTPA Ester Derivatives of 1-4. To a stirred solution of 1 (6.0 mg) in pyridine (400 μL) was added 4-(dimethylamino)pyridine (3 mg) and (S)-(+)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride (MTPA-Cl, 10 μL). The mixture was stirred at room temperature for 16 h. The reaction mixture was then passed through a silica gel Waters Sep-Pak Vac 6cc and eluted with n-hexane-EtOAc (1:1) to give the respective (R)-Mosher ester 1r. Treatment of 1 (6.0 mg) with (R)-MTPA-Cl (10 μL) as described above yielded the corresponding (S)-MTPA ester 1s. Similarly, treatment of 2-4 with (S)-and (R)-MTPA-Cl afforded the respective Mosher esters 2r, 2s, 3r, 3s, 4r, and 4s.
A detailed description of the bioassays is available as the Supporting Information. The positive control, doxorubicin (purity ≥ 98%) was purchased from the Sigma Corporation. 
